Kornimate/medical-research-clean huggingface dataset:
adjuvant curcumin to assess recurrence free survival in patients who have had a radical prostatectomy

Conditions: Prostate Cancer

Summary: this is a prospective study to determine if the adjuvant use of curcumin improves recurrence-free survival.

this is a prospective study to determine if the adjuvant use of curcumin improves recurrence-free survival in patients after radical prostatectomy compared to placebo

Eligibility criteria:
inclusion criteria: * status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate * pathologically confirmed t1-t3 disease * no sign of lymph node or metastatic disease * pt1-pt3pnxmx patients in whom standard nccn or aua guidelines would suggest are at low risk for pelvic lymph node or metastatic disease and who would not require confirmatory imaging for metastatic disease. this includes patients with gleason 6 or 7(t2 disease) and psa less than 20. * eastern cooperative oncology group(ecog) status 0-2 * adequate renal and liver function as well as bone marrow reserve (measured serum creatinine \<2mg/dl, bilirubin ≤ 1.5 mg/dl, anc ≥ 1.5 x 10 (3) ul, platelets ≥ 50 x k/ull, and hemoglobin ≥ 10 g/dl) * 30-80 y/o at time of diagnosis with a life expectancy of \>= 3 yrs * focally positive surgical margins are permitted * no plan to receive adjuvant hormone or radiation therapy * psa at the time of enrollment must be undetectable * life expectancy of 3 years exclusion criteria: * must not have exceeded 3 months from time of surgery to enrollment into study * t3b or t4 or node positive disease * macroscopic residual disease after surgery * hormone therapy before surgery * history of gallbladder problems or gallstones, or biliary obstruction, unless patient had cholecystectomy * radiation therapy as primary treatment after surgery * inr value greater than 1.5 * ast/alt are equal or greater than 2 times the upper limit of normal * antiplatelet or anticoagulant agents- patients taking 81mg of aspirin will be allowed with close observation * history of gastric or duodenal ulcers or untreated hyperacidity syndromes * patients who are currently taking curcumin and are unwilling to stop or plan to take curcumin during the study

Keywords: prostate cancer radical prostatectomy
prevention allergic disease of infant with probiotics during pregnancy and neonatal period

Conditions: Atopic Dermatitis; Allergic Rhinitis; Asthma

Summary: the purpose of this study is to determine whether childhood atopic disease decrease or not after allowing allergic mothers intake of probiotic (lactobacillus gg) in second trimester, followed by infant intake for 6 months after birth.

the prevalence of atopy at taiwan increased 8 times in past 20 years and also increased all over the world. in our previous study, maternal atopic history rather than paternal one is the major factor to effect infant eczema and ige titers. this may be related to maternal inheritance and environments during pregnancy. kalliomaki et al. (lancet, vol.357, p1076-9, 2001) presented that lactobacillus gg used 2-4 weeks prenatally to mothers and 6 months postnatally to infants was effective in prevention of early atopic disease in children at high risk. we designed a double-blind randomized placebo-controlled study to evaluate whether cord blood ige and childhood atopic disease decreased after allowing allergic mothers intake of lactobacillus gg in second trimester, followed by infant intake of lactobacillus gg for 6 months after birth. materials and methods: 1. inclusion criteria: pregnant women with atopic disease, which was determined with atopic history, elevated total ige \> 100 ku/l and positive specific ige. 2. case number: 100 cases were collected in both control and study groups. 3. study design: in a double blind randomized placebo-controlled study, eligible cases are allowed to take lactobacillus gg or placebo daily from gestational age of 24 weeks until delivery in both groups. in study group, lactobacillus gg is given prenatally from gestational age of 24 weeks to delivery for mothers and 6 months postnatally for infants. in control group, placebo starch is given prenatally from gestational age of 24 weeks for mothers to delivery and 6 months postnatally for infants. 4. schedule of follow-up: infant/child clinical symptoms and sign are evaluated and ige and specific ige are tested in bloods from umbilical cords, infants in 1, 3 and 5 year old.

Eligibility criteria:
inclusion criteria: * pregnant women with atopic disease, which was determined with atopic history, elevated total ige \> 100 ku/l and positive specific ige exclusion criteria: * multiple pregnancy

Keywords: lactobacillus rhamnosus atopic dermatitis allergic rhinitis asthma infant pregnancy
assessment of lbr-101 in chronic migraine

Conditions: Chronic Migraine

Summary: the purpose of the study is to determine whether monthly subcutaneous administration of lbr-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.

two distinct doses of subcutaneous lbr-101 (fremanezumab) administered monthly will be compared to placebo for safety and efficacy. the mean change from baseline in the number of cumulative headache hours measured at the 28-day period ending with week 12.

Eligibility criteria:
inclusion criteria: * males or females aged 18 to 65 years of age. * a signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study including any known and potential risks and available alternative treatments. * chronic migraine meeting the diagnostic criteria listed in the international classification of headache disorders (ichd-iii beta version, 2013) * body mass index (bmi) of 17.5 to 37.5 kg/m2, and a total body weight between 50 kg and 120 kg inclusive. * demonstrated compliance with the electronic headache diary during the run-in period headache data on a minimum of 22/28 days (80% diary compliance) exclusion criteria: * onset of chronic migraine after the age of 50 years. * subject has received onabotulinum toxin a for migraine or for any medical or cosmetic reasons requiring injections in the head, face, or neck during the 6 months prior to study entry. * subject is using medications containing opioids (including codeine) or barbiturates (including fiorinal®, fioricet®, or any other combination containing butalbital) on more than 4 days per month for the treatment of migraine or for any other reason. * failed \> 2 medication categories or \> 3 preventive medications (within two medication categories) due to lack of efficacy for prophylactic treatment of episodic or chronic migraine after an adequate therapeutic trial * treatment with an investigational drug or device within 30 days of study entry or any prior exposure to a monoclonal antibody targeting the cgrp pathway.

Keywords: headache migraine chronic migraine
hero study: helping evaluate reduction in obesity

Conditions: Obesity

Summary: a prospective, international, multi-center study of clinical outcomes and estimated healthcare resource expenditures associated with the treatment of obesity using the lap-band ap® adjustable gastric banding system.


Eligibility criteria:
inclusion criteria: * patient and investigator have made a decision, independent of the study, to proceed with lap-band ap® implantation. * male or female aged ≥ 18 years. * bmi ≥ 40 or a bmi ≥ 35 with one or more severe co-morbid conditions, or those who are 45.5 kg / 100 lbs or more over their estimated ideal weight. exclusion criteria: * prior bariatric surgery. * type i diabetes patients. * participating in another ongoing clinical study with concomitant diagnostic or therapeutic intervention that would reasonably be expected to alter patterns of care, use of medications or the outcomes under study.
a trial of e-cigarettes in current cigarette smokers

Conditions: Smoking; Nicotine Dependence; Nicotine Dependence, Other Tobacco Product

Summary: the purpose of this study is to examine cigarette smokers' use of electronic cigarettes (e-cigarettes), and how use of e-cigarettes affects short term smoking behavior.

study initiation will commence after the first telephone contact (phone pre-screen), at the baseline visit. additional lab visits will occur at days 8, 15, and 22 (visits 2-4). at the first study visit, 2/3rds of the participants will be randomly assigned to sample e-cigarettes and 1/3rd will not. participants in the e-cigarette group will be provided with sufficient product to sample and use as they wish, but with minimal instruction on purpose and level of use (non-use is an outcome). smokers in the control group will smoke their own brand of cigarettes, as they wish, for the duration of the sampling period. all participants will engage in ecological momentary assessments, which will be completed 3 times daily for 3 weeks. in-person follow-up assessments will be conducted at 1, 2, and 3 months after the final lab visit (day 22). overall, each participant will be contacted 8 times: at the phone pre-screening, the 4 lab visits, and 3 follow-up visits.

Eligibility criteria:
inclusion criteria: * age 18+ * current smoker of at least 5 cigarettes per day for at least 1 year * at least some concern for health effects of smoking * having an easily accessible email address exclusion criteria: * past six month use of any e-cigarette * lifetime ever purchase of any e-cigarette * recent history of cardiovascular distress (heart attack in past year; arrhythmia; uncontrolled hypertension) * recent history (past 3 months) of chronic obstructive pulmonary disease (copd), cancer (any non-dermatologic), or uncontrolled diabetes mellitus * pregnant or breastfeeding * any major current psychiatric impairment, including current alcohol/drug abuse/dependence * use of non-cigarette tobacco products (e.g., cigarillos) in the last 30 days * current use of any smoking cessation medications * current enrollment in a smoking cessation treatment study

Keywords: smoking nicotine tobacco products electronic cigarette
pelvic floor muscle activity in primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: this study will be conducted to assess the pelvic floor muscle (pfm) activity in primary dysmenorrhea (pd).

dysmenorrhea, marked by painful menstrual cramps, often involves increased pfm tension, spasms, and inflammation, affecting females' quality of life and productivity. the traditional focus has been on investigating the abdominal region in women with pd. however, this new perspective considers that the hormonal changes experienced during the menstrual cycle in pd patients may lead to a heightened sensitivity of the pfm, not just the abdominal area. this suggests that the pain associated with pd may have a more widespread impact on the pelvic region rather than being localized to the abdomen. pelvic floor myofascial trigger points (mtrps) may also exacerbate menstrual pain through the neural pathway. there is a critical gap in the literature regarding the nature of the association between dysmenorrhea and pfm activity in this population. yet, it is unknown whether the pain is a cause or result of increased pfm tone, and the nature of the association between menstrual pain and pfm tone in women with pd is also unknown. so, this study utilizes transabdominal ultrasound (tau) to examine pfm activity in pd, aiming to clarify how pfm activity contributes to menstrual pain. understanding these dynamics could lead to preventive strategies and educational efforts highlighting the role of pelvic floor interventions in managing dysmenorrhea, potentially improving treatment methods and overall women's health management.

Eligibility criteria:
inclusion criteria: * they should be virgin, healthy female physiotherapy students with pd. * they have regular menstruation (3-8 days in duration, with 21-35 days in between). * their ages will range from 18 to 25 years old. * their body mass index (bmi) will range from 18 to 24.9 kg/m2. * their waist-to-hip ratio will be less than 0.8. exclusion criteria: * any urological or gynecological disorders in the previous 12 weeks (e.g., endometriosis, fibroids). * fibromyalgia. * severe psychiatric or psychological disorders. * those who had taken analgesics in the 12 hours before the assessment. * abdominal or pelvic surgery within the past six months.
the combination of sitagliptin and danazol as the treatment of steroid-resistant/relapse immune thrombocytopenia

Conditions: Immune Thrombocytopenia; Blood Coagulation Disorders; Thrombocytopenia; Physiological Effects of Drugs

Summary: randomized, open-label, multicenter study to compare the efficacy and safety of combination of sitagliptin and danazol versus danazol for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (itp).

the investigators are undertaking a parallel group, multicenter, randomized controlled trial of 120 adults with steroid-resistant/relapse itp in china. patients were randomized to sitagliptin plus danazol and danazol monotherapy group. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study.

Eligibility criteria:
inclusion criteria: primary immune thrombocytopenia (itp) confirmed by excluding other supervened causes of thrombocytopenia; platelet count of less than 30×109/l at enrollment; patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation; 18 years older; exclusion criteria: secondary immune thrombocytopenia (e.g., patients with hiv, hcv, helicobacter pylori infection or patients with systemic lupus erythematosus) congestive heart failure severe arrhythmia nursing or pregnant women aspartate aminotransferase and alanine transaminase levels ≥ 3× the upper limit of the normal threshold criteria creatinine or serum bilirubin levels each 1•5 times or more than the normal range active or previous malignancy unable to do blood routine test for the sake of time, distance, economic issues or other reasons.

Keywords: sitagliptin immune thrombocytopenia danazol
biomarkers of intestinal fibrosis in small bowel crohn's disease

Conditions: Crohn Disease

Summary: this research study will evaluate if specific blood, stool and mri tests can tell the difference between bowel wall inflammation without scarring and bowel wall inflammation with scarring that can cause bowel blockages requiring surgery.

this multi-center study will test the accuracy of individual and combined mri and blood-based diagnostic tools in both children and adults with small bowel cd. we will determine the accuracy of a composite tool (including its multiple individual biomarkers) for defining the relative amounts of intestinal inflammation versus scarring in patients at the time of surgery (b2 disease) and in patients at an early stage of disease prior to complications (b1 disease).

Eligibility criteria:
inclusion criteria: * aim 1 (cd participants) 1. aged 8-70 years 2. undergoing first surgical distal (ileal) small bowel resection for structuring (b2 phenotype) crohn's disease as determined by cte or mre or ileocolonoscopy 3. english speaking * aim 2 (cd participants) 1. age 8 to 70 years 2. uncomplicated inflammatory small bowel cd based on clinical cte or mre or ileocolonoscopy performed within 6 months prior to enrollment (cd participants only) 3. english speaking * aim 2 (control participants) 1. age 8 to 70 years 2. english speaking exclusion criteria: * aim1 (cd participants) 1. b1 or b3 (i.e., fistula, abscess, phlegmon/inflammatory mass) cd phenotype 2. prior small bowel surgery, including but not limited to surgical resection, stricturoplasty, or endoscopic treatment of a small bowel stricture 3. anything to eat or drink within 4 hours of study visit (participants may take their required medications with a little water) 4. known pregnancy (note: institutional policies/procedures will be followed for pregnancy screening) 5. contraindication for mri (e.g., surgical implant, claustrophobia). note: to be determined based on local procedures. * aim 2 (cd participants) 1. stenotic ileocecal valve at colonoscopy 2. prior small bowel surgery, including but not limited to surgical resection, stricturoplasty, or endoscopic treatment of a small bowel stricture 3. anything to eat or drink within 4 hours of study visit (participants may take their required medications with a little water) 4. known pregnancy (note: institutional policies/procedures will be followed for pregnancy screening) 5. contraindication for mri (e.g., surgical implant, claustrophobia). note: to be determined based on local procedures. * aim 2 (control participants) 1. any known gastrointestinal tract disease 2. any known inflammatory/autoimmune disease involving another organ system (e.g., rheumatoid arthritis, scleroderma, multiple sclerosis). 3. fecal calprotectin level of ˃100 mcg.gm will be excluded from further analysis and replaced.
socio-educational intervention for rural suicide attempters

Conditions: Suicide, Attempted

Summary: compared to a treatment-as-usual group, providing brief mental health education to suicide attempters from rural parts of china at the time of their treatment in the emergency departments of general hospitals or local clinics and 6 home-visits (for those subjects with phones refuse home visits, the interviews will be conducted over the phone) over the twelve months after the attempt demonstrate continuing concern about the attempters ('befriending'), strengthen their social support networks and improve their problem-solving skills will significantly reduce their hopelessness, the severity of depressive symptoms, and level of suicidal ideation.


Eligibility criteria:
inclusion criteria: * suicide attempters * must be 18 years or older * no-zero intent to die exclusion criteria: * with communication difficulties * living outside of the research sites

Keywords: attempted suicide socio-educational intervention follow up study
pattern of chronic disease in adult attendantsabove18years old in new vally elkharga family medicine clinic

Conditions: Chronic Wasting Disease of Elk and Deer; Injury; Knee, Meniscus, Old Injury or Tear

Summary: globally one in three of all adult suffer from multible chronic condition six in ten adult has achronic disease and four in ten adult have twoor more.it has been calculated that 58million death in2005 approximately 35million will be aresult of chronic disease health damaging behavior tobbaco use, poor physical activity and poor eating habbits are major contributors to the leading chronic diseases the leading chronic diseases in developed countries including arthritis, cardiovascular diseases,heart attacks,stroke,cancer, diabetes,breast\&colonic cancer , aging increasing the risk of chronic diseases like dementia ,heart diseases,cancer these are the nation's leadingdrivers of illness,disability,death and health care costs.

in2008 more than1,2million people died from non communicable diseases accounting for nearly 60% of all death inthe region with wide several outbreaks of hospital acquired infection in the midlle east have occurredwith substantial morbidity and mortality.egypt currently has the third highest prevelance of obesity inmena region after saudi arabia and emirates similar to the hispanic and native.american population central adiposity is particularly common among egyptienand is probably inherited the egyptian national survey individual have central obesity.this be found strongly associated with increase risk of dm and cardiovascular diseases

Eligibility criteria:
inclusion criteria: * attendands above18years exclusion criteria: * attendants below18 years
tubal factor in unexplained infertility

Conditions: Infertility of Tubal Origin

Summary: ray and colleagues define "unexplained infertility" as failure to achieve pregnancy when the semen analysis is normal, evidence for ovulation is present, and tubal patency has been established. the efficacy of treatment declines with increasing age and duration of infertility infertility is a disease , defined by the failure to achieve a successful pregnancy after 12 months or more of appropriate, timed unprotected intercourse or therapeutic donor insemination, barber evaluation and treatment may be justified based on medical history and physical findings and is warranted after 6 months for women over age 35 years. in unexplained infertility abnormalities are likely to be present but not detected by current methods including semen analysis in the man, assessment of the state of ovulation, ovulation reserve and patency of uterine tubes in the woman. unexplained infertility is not a rare item of infertility. approximately 15% of infertility couple will be diagnosed with unexplained infertility after their diagnostic workup many researches studied the laparoscopic tubal factor like tubo-ovarian relation, tubal kinks and fimbrial pathology. but we need to scope on more tubal factors like fatty mesosalpinx , fimbria ovarica, methylene blue free spill and others


Eligibility criteria:
inclusion criteria: * women with unexplained infertility. * women in reproductive period between 20 and 35 years. * primary or secondary infertility exclusion criteria: * with age less than 20 years and more than 35 years old * other causes of infertility other than tubal factor * other contraindications for laparoscopy
treatment of copd by autologous transplantation of bronchial basal cells

Conditions: Chronic Obstructive Pulmonary Disease

Summary: bronchial basal cells are proved to be able to regenerate lung structures to repair the injured lung. in copd patients, bronchus structures are injured and cannot be repaired, which may result in the failure of pulmonary function rescue clinically.in our research, autologous bronchial basal cells will be transplanted into lung of patients suffered with copd to treat the disease. specifically, autologous bronchial basal cells will be dissected from brushed-off samples by bronchofiberscope. then, they will be expanded in vitro and transplanted into lung to regenerate new alveoli and bronchus structures and re-establish pulmonary system.


Eligibility criteria:
inclusion criteria: * aged between 40 to 75; * diagnosed with copd according the guideline (a. with symptoms of productive cough, sputum production or shortness of breath; b. with poor airflow as indicated by fev1\<70% predicted value and fev1/fvc \< 0.7 in pulmonary function test; c. with exclusion of other pulmonary disease by ct or blood examination); * clinically stable for more than 4 weeks; * tolerant to bronchofiberscope; * written informed consent signed. exclusion criteria: * pregnant or lactating women; * patients positive for syphilis, hiv; * patients with malignant tumor; * patients with serious or significant pulmonary infection and need anti-infection treatment; * patients with serious heart disease(nyha class ⅲ-ⅳ); * patients with a history of abusing alcohol and illicit drug; * patients participated in other clinical trials in the past 3 months; * patients assessed as inappropriate to participate in this clinical trial by investigator.